Formulation and Characterization of Isradipine Nanoparticle for Dissolution Enhancement

Isradipine belong to dihydropyridine (DHP) class of calcium channel blockers (CCBs). It is used in the treatment hypertension, angina pectoris, addition Parkinson disease. goes under BCS II drug (low solubility-high permeability). The will experience extensive first-pass metabolism liver, therefore, oral bio-availability be approximately15 24 %.
 
 aim this study was formulate and optimize a stable nanoparticles highly hydrophobic drug, isradipine by anti-solvent microprecipitation Method achieve higher vitro dissolution rate, so that it absorbed intestinal lymphatic transport order avoid hepatic improve bioavailability.
 Twenty one formulas were prepared antisolvent precipitation method utilizing these polymers (Poloxamer 188, PVP-k30, HPMC E5, PVA, Poloxamer 407, Soluplus) at different drugs: polymer ratios. type, ratio, ultrasonication power effect co-stabilizer on particle size, polydispersity index (PDI) investigated.
 Among all formulas, formula (F9) which contain Soluplus as stabilizer polymer: ratio (1:0.75) solvent: (1:9) considered optimum shows good evaluation parameters increment solubility about 10 times than pure drug. investigations drug–excipients compatibility studies FTIR DSC, crystalline state P-XRD, surface morphology SEM done. Moreover, analysis DSC selected (F12) indicate reduction crystallinity amorphization can concluded rate significantly increased through size nanosize.